Dr Daniel Krell
Consultant Medical Oncologist
DPHIL, MRCP, MBCHB, BSC
Dr Daniel Krell qualified in medicine at Leeds University Medical School, where he also gained a Bachelor’s degree in immunology and microbiology. He completed his junior doctor training at Leeds General infirmary in Leeds and at Guys and St. Thomas’ Hospitals and University College Hospital in London before undertaking his oncology training at The Royal Free and University College Hospitals in London.
About Dr Daniel Krell
Dr Krell’s DPhil research was undertaken at The University of Oxford, Wellcome Trust Centre for Human Genetics, funded by Cancer Research UK and HCA.
Dr Krell’s research investigated the role that genetic mutations in genes controlling cellular metabolism play in the development of cancer, with a view to identifying new therapeutic targets in this area. He continues to be involved in clinical research and clinical trials aimed at identifying new cancer therapies, with a focus on gastrointestinal and hepatobiliary malignancies.
Dr Krell has published in several peer-reviewed papers in journals such as the British Journal of Cancer and Lancet Oncology and has submitted and presented abstracts and posters at national and international conferences.
His clinical work focuses on the management of patients with gastro-oesophageal, colorectal, pancreatic, liver and biliary tract cancers using chemotherapy, targeted therapy and immunotherapies.
He also manages patients with cancer of unknown primary and is the clinical lead at Barnet hospital.
He acts as the MDT lead for gastro-oesophageal and hepatobiliary cancer at his institution and is a member of the London cancer expert reference group for acute oncology and cancer of unknown primary.
- The systemic treatment of colorectal
- Pancreatic and liver and bile duct cancers and cancer of unknown primary
- DPhil in clinical medicine obtained from the Wellcome Trust Centre for Human Genetics, University of Oxford.
- Establishing links between genetic mutations in genes involved in cellular metabolism and the development of cancer
- Involvement in clinical trials of new therapies for gastrointestinal and hepatobiliary cancers
Like to book an appointment?
Fill out the contact form below or call us on
020 7317 7751 to speak with a member of our team
- Targeted therapy and immunotherapy for the treatment of Gastrointestinal and hepatobiliary cancer
Multi-Centre randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. Brown N, McBain C, Nash S, Hopkins K, Sanghera P, Saran F, Phillips M, Dungey F, Krell D, Jeffries S, Khan I, Smith P, Mulholland P. PLOS ONE May 2016.
HOT mutation screening in human glioblastoma. Future Science OA, FSO22, DOI: 10.4155/FSO.15.20 (2015).Krell D, Mulholland P, Stebbing J, Tomlinson I, Bardella C.
AT-43* Multi-centre, randomised double-blind phase II study comparing Cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. Neuro-oncology 16: V8-22. 2014. Doi:10.1093/neuonc/neu237. Mulholland P, Krell D, Khan I, McBain C, Patel C, Wanek K, Hopkins K, Jeffries S, Jager R, Smith P, Liu Q, Stupp R, Tomlinson I.
microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. Eur J Cancer. 2015 Jul; 51(11):1389-404. Frampton AE, Krell J, Jamieson NB, Gall TM, Giovannetti E, Funel N, Mato Prado M, Krell D, Habib NA, Castellano L, Jiao LR, Stebbing J.
IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol. 2013 Dec; 9(12): 1923-35. Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C.
The Malignant Truth. Lancet Oncol. 2013 Jan;14(1): 25-6. Krell D, Stebbing J. Aristolochia
Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Expert Rev Anticancer Ther. 2012 Oct;12(10): 1275-8. Frampton AE, Krell J, Giovannetti E, Krell D, Stebbing J, Castellano L, Jiao LR.
Retrospective Analysis of Primary Tumour Histology and Survival in Breast Cancer Patients Developing Symptomatic Brain Metastases Treated with Whole Brain Radiotherapy (WBRT) at Mount Vernon Cancer Centre (MVCC). Cancer Research: 2009 Dec; Vol 69, Issue 24, Supplement 3. Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma. PLoS One. 2011; 6(5): e19868Miller R, Assoku M, Krell D, Sasieni P, Mulholland P. A
What is the evidence for rechallenging with anthracyclines or taxanes in metastatic breast cancer- A review of the data. J Clin Oncol 27:15s, 2009 (suppl; abstr 1072). Krell J, Harper-Wynne C, Miles D, Misra V, Cleator S, Krell D, Palmieri C.
Impact of the effective prevention and management of febrile neutropaenia. Br J Cancer. 2009 Sep;101 Suppl 1:S23-6. Krell D, Jones A.